Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A

Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A

285724

Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A

A single dose of the experimental gene therapy SPK-8016 showed promising safety and efficacy in lowering the frequency of bleeds and the need for infusions in men with severe hemophilia A. These preliminary findings from an ongoing Phase 1/2 trial (NCT03734588) were presented by Spencer Sullivan, MD, a researcher at the Mississippi Center for Advanced Medicine, at the European Association for Haemophilia and Allied Disorders 2021 Virtual Congress, held online Feb. 3–5. SPK-8016 is an…

You must be logged in to read/download the full post.